ALBUQUERQUE, N.M., March 22 /PRNewswire/ -- Protalex, Inc.
(OTC Bulletin Board: PRTX), a biopharmaceutical firm, announced today two
significant milestones in its recent history. First, the company, formerly
known as Enerdyne Corporation, has returned to trading on the OTC Bulletin
Board with a new symbol (PRTX) and a new mission: developing a novel approach
to treating Rheumatoid Arthritis. Second, the company announced the
successful completion of the cell culture phase of its research plan, and the
beginning of animal studies of its unique BioRegulator product. John Doherty,
Protalex's President, announced, "The Protalex BioRegulator drug methodology
operates on a completely different principle than existing treatment regimens.
It works with the host's own natural defense system to arrest the disease
process, rather than simply masking the symptoms."
The unique Protalex technology is based upon discoveries made by Paul
Mann, Ph.D., over decades of research into the immune system. Dr. Mann, a
Director of the Company and head of Research and Product Development, has
explored the properties of several products that affect the "information
management" mechanisms in the body. Cells normally communicate with each
other by chemical signals that pass back and forth to keep their functions in
balance. In many disease states, it is thought that erroneous signals cause
garbled messages that lead to abnormal cell function and tissue damage. Dr.
Mann discovered that certain natural and synthetic compounds can restore
aspects of the normal balance between tissues, halting the disease process
itself. This means that treatment can be discontinued once normal tissue
functioning is re-established. Furthermore, if the disease process is one
that involves differentiation of cells, some degree of repair of damaged
tissues should be expected. These concepts are crucial for the treatment of
Rheumatoid arthritis affects more than 2 million people in the United
States alone, most of whom are less than 65 years old. Presently there is no
effective cure for this chronic and disabling disorder, and available
medications provide variable relief of symptoms but have only minimal effect
upon the disease process. The Protalex BioRegulator product promises to be
the prototype for an entirely new class of drugs that can arrest or even
reverse the course of the disease and thereby restore the quality of life for
hundreds of thousands of people suffering from Rheumatoid Arthritis.
Statements in this press release that are not strictly historical are
"forward-looking" statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements involve a high degree of risk and uncertainty, are
predictions only and actual events or results may differ materially from those
projected in such forward-looking statements. Factors that could cause or
contribute to differences include the Company's limited operating history,
uncertainty regarding viability and market acceptance of the Company's
products, and the Company's dependence on reimbursement by third parties.
These factors and others are more fully described in the section entitled
"Risks Related to the Company's Business" in the Company's Registration
Statement on Form 10-SB (File No. 000-28385) as filed with the Securities and
SOURCE Protalex, Inc.